Multi-Omics Data Integration Reveals Emerging Targets for RAS Mutant Cancers
Time: 2:50 pm
day: Day Two
- Targeting KRAS has proven clinical value for G12C mutant tumors – can this be expanded by a new wave of target ID, with distinct activity in intrinsic or acquired resistant models to G12C inhibition?
- Utilizing a combination of KRASG12Ci Resistant cell line models, and in vivo CRISPR drop out screens, reveals new targets required for the tumor maintenance of RAS mutant cancers
- Rationale for predicting biomarker response to emerging targets beyond RAS mutational status